Allogene Therapeutics Stock News

Victory Capital Management Inc. boosted its position in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 41.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 12,364 shares of the

Allogene Therapeutics (NASDAQ:ALLO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to

SOUTH SAN FRANCISCO, Calif., April 01, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.

Allogene Therapeutics (NASDAQ:ALLO) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Va

Allogene Therapeutics (NASDAQ:ALLO) and Orchard Therapeutics (NASDAQ:ORTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of

Bainco International Investors lessened its position in Allogene Therapeutics Inc (NASDAQ:ALLO) by 78.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 76,650 sha

Alliancebernstein L.P. increased its holdings in Allogene Therapeutics Inc (NASDAQ:ALLO) by 10.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stoke Therapeutics (STOK), Allogene Therapeutics (ALLO) and

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stoke Therapeutics ( STOK – Research Report ), Allogene Therapeutics ( ALLO – Research Report ) and

Since my last article on Allogene Therapeutics about 5 months ago, its share price has fallen by around 30%. I was bearish on the company’s short-term prospects

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa

Zacks Investment Research downgraded shares of Allogene Therapeutics (NASDAQ:ALLO) from a buy rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. According to